IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Authors:
- Mark AyersMAMark Ayers
- Jared LuncefordJLJared Lunceford
- Michael NebozhynMNMichael Nebozhyn
- Erin MurphyEMErin Murphy
- Andrey LobodaALAndrey Loboda
- Andrew AlbrightAAAndrew Albright
- S. Peter KangSKS. Peter Kang
- Veena ShankaranVSVeena Shankaran
- Sarina A. Piha-PaulSPSarina A. Piha-Paul
- Jennifer YearleyJYJennifer Yearley
Top Cited Papers
Open Access
- 26 June 2017
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (8) , 2930-2940
Abstract
Programmed death-1–directed (PD-1–directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti–PD-1 therapies, including pembrolizumab. However, whether quantifying T cell–inflamed microenvironment is a useful pan-tumor determinant of PD-1–directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell–inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell–inflamed GEP contained IFN-γ–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell–inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.Keywords
This publication has 29 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancerVirology Journal, 2011
- Interferon-γ links ultraviolet radiation to melanomagenesis in miceNature, 2011
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- The function of programmed cell death 1 and its ligands in regulating autoimmunity and infectionNature Immunology, 2007
- Regularization and Variable Selection Via the Elastic NetJournal of the Royal Statistical Society Series B: Statistical Methodology, 2005
- Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responsesEuropean Journal of Immunology, 2003
- The roles of IFNγ in protection against tumor development and cancer immunoeditingCytokine & Growth Factor Reviews, 2002